Go to
JCI Insight
About
Editors
Consulting Editors
For authors
Publication ethics
Publication alerts by email
Advertising
Job board
Contact
100th anniversary
Current issue
Past issues
By specialty
COVID-19
Cardiology
Gastroenterology
Immunology
Metabolism
Nephrology
Neuroscience
Oncology
Pulmonology
Vascular biology
All ...
Videos
Conversations with Giants in Medicine
Video Abstracts
Reviews
Reviews
View all reviews ...
Review Series
Substance Use Disorders (Oct 2024)
Clonal Hematopoiesis (Oct 2024)
Sex Differences in Medicine (Sep 2024)
Vascular Malformations (Apr 2024)
Lung inflammatory injury and tissue repair (Jul 2023)
Immune Environment in Glioblastoma (Feb 2023)
Korsmeyer Award 25th Anniversary Collection (Jan 2023)
View all review series ...
Viewpoint
Collections
In-Press Preview
Clinical Medicine
Research Letters
Letters to the Editor
Editorials
Commentaries
Reviews
Viewpoints
Top read articles
Clinical Medicine
How should we think about the unprecedented weight loss efficacy of incretin-mimetic drugs?
Yang Gou, Michael W. Schwartz
Yang Gou, Michael W. Schwartz
Published October 2, 2023
Citation Information:
J Clin Invest.
2023;
133(19)
:e174597.
https://doi.org/10.1172/JCI174597
.
View:
Text
|
PDF
Viewpoint
How should we think about the unprecedented weight loss efficacy of incretin-mimetic drugs?
Text
PDF
Abstract
Authors
Yang Gou, Michael W. Schwartz
×
Full Text PDF |
Download
(670.12 KB)
